跳至主要内容

博文

目前显示的是标签为“药品审评报告”的博文

国内药品审评报告Drug Review Package of Chinese New Chemical or Biologic Drug

Belows are the drug review package of Chinese new chemical or biologic drug : Benaglutide   (贝那鲁肽, HYBR-014, GLP-1) was developed by  Benemae Pharma  (filing for STAR), approved in 2016/12/19, click  here . Anlotinib   (安罗替尼, AL3818, VEGFR/FGFR/PDGFR) was developed by  Chia Tai Tianqing Pharma  (HK: 01177), approved in 2018/5/9, click  here . Mecapegfilgrastim  (硫培非格司亭, 19K, G-CSF) was developed by  Hengrui Medicine  (SH: 600276), approved in 2018/5/18, click  here . Pyrotinib   (吡咯替尼, SHR-1258, HER2) was developed by  Hengrui Medicine  (SH: 600276),  approved in 2018/8/12, click  here . Fruquintinib  (呋喹替尼, HMPL-013, VEGFR) was developed by  Hutchison MediPharma  (NASDAQ: HCM), approved in 2018/9/5, click  here . Toripalimab  (特瑞普利单抗, JS001, PD-1) was developed by  Junshi Biosciences  (HK: 01877/filing for STAR), approved in 2018/12/17, click  here . Sintilimab  (信迪利单抗, IBI308, PD-1) was developed by  Innovent Biologics  (HK: 01801), approved in 2018/12/27, click  here . Camrelizumab